Evidence map›Paper›PMID 40630095›Full record

ArticleFrontiers in endocrinology2025

EZH2 promotes endometriosis progression through estrogen receptor and TNFα expression.

Xiaohan Liu, Liqin Cheng, Liuxuan Huang, Mingyue Li, Qingjun Shen, Donghan Li, Kailing Dai, Yanxia Fu, Min Li, Paul Yao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaohan Liu *Department of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Liqin Cheng *Department of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Liuxuan HuangDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Mingyue LiDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Qingjun ShenDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Donghan LiDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Kailing DaiDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Yanxia FuDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Min LiInstitute of Burns, Tongren Hospital of Wuhan University (Wuhan Third Hospital), Wuhan, China.
Paul YaoDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
Liqin ZengDepartment of Gynecology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometriosis is a chronic inflammatory gynecological condition marked by the presence of tissue similar to the endometrium grows outside the uterus, often leading pelvic pain and infertility. This study explores how enhancer of zeste homolog 2 (EZH2) influences endometriosis, particularly through its interaction with estrogen receptors (ERs). We found that EZH2 reduces ERα expression, allowing ERβ to bind to the tumor necrosis factor α (TNFα) promoter and increase TNFα levels, fueling inflammation. In mice, the EZH2 inhibitor GSK343 reduced TNFα levels and endometriosis progression, similar to gene knockdown of ERβ or EZH2. In human samples, endometriotic tissue showed higher levels of EZH2 and ERβ and lower levels of ERα than in controls. Thus, EZH2 promotes TNFα-driven inflammation, contributing to endometriosis. Targeting EZH2, as with GSK343, could be a promising therapeutic strategy for endometriosis treatment.

Indexed as

EndometriosisEnhancer of Zeste Homolog 2 ProteinEstrogen Receptor alphaEstrogen Receptor betaReceptors, EstrogenTumor Necrosis Factor-alphaAnimalsDisease ProgressionEndometriumFemaleHumansIndazolesMicePyridonesEnhancer of Zeste Homolog 2 ProteinEstrogen Receptor alphaEstrogen Receptor betaEZH2 protein, humanGSK343IndazolesPyridonesReceptors, EstrogenTumor Necrosis Factor-alphaendometriosisestrogen receptorEZH2inflammationTNFα

Identifiers

PMID40630095
PMCPMC12234293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.